Antipsychotic Boxed Warning Will Caution Against Off-Label Use In Dementia
Executive Summary
FDA is asking manufacturers of atypical antipsychotics to add a "black box" warning to labeling on an increased mortality risk associated with the drugs' off-label use to treat dementia-related behavioral disorders
You may also be interested in...
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
FDA put its new labeling authority under the FDA Amendments Act on public display June 16 by directing makers of conventional antipsychotics to add to their drugs' prescribing information a boxed warning about use in elderly patients with dementia
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
FDA put its new labeling authority under the FDA Amendments Act on public display June 16 by directing makers of conventional antipsychotics to add to their drugs' prescribing information a boxed warning about use in elderly patients with dementia
Antipsychotics Commonly Used Off-Label By Dementia Patients, AHRQ Finds
About 25 percent of people with dementia living in either a community setting or long-term care facility receive cholinesterase inhibitors, a government-funded study found